Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac433
Abstract: found that crushed posaconazole DR tablets given per feeding tube at a dose of 300 mg daily produced therapeutic levels after 2 weeks of therapy in 19 of 19 patients receiving treatment for rhino-orbito-cerebral mucormycosis.… read more here.
Keywords: nirmatrelvir ritonavir; crushed posaconazole; tube; use nirmatrelvir ... See more keywords
Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dky539
Abstract: BACKGROUND Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are available in immunocompetent hosts such as those with chronic pulmonary aspergillosis (CPA). OBJECTIVES To explore the pharmacokinetics and adverse… read more here.
Keywords: posaconazole tablets; chronic pulmonary; aspergillosis; pulmonary aspergillosis ... See more keywords
Alternate‐day dosing of posaconazole tablets in children leads to efficient plasma levels
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Haematology"
DOI: 10.1111/ejh.13063
Abstract: Invasive fungal diseases (IFD) are a major cause of morbidity and mortality in immunocompromised children, especially those undergoing allogeneic hematopoietic stem cell transplantation (HSCT) [1].Recently Vicenzi et al highlighted the role of posaconazole oral suspension in… read more here.
Keywords: posaconazole tablets; plasma; day dosing; plasma levels ... See more keywords